Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways-Reference-Cited by-同舟云学术

Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways

Published:2016-10-22 Issue:6 Volume:100 Page:730-742
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Faulkner SD¹,Lee M²,Qin D²,Morrell L¹,Xoxi E³,Sammarco A³,Cammarata S³,Russo P³,Pani L³,Barker R¹

Affiliation:

1. Centre for Advancement for Sustainable Medical Innovation (CASMI); University of Oxford; Oxford United Kingdom

2. Price Waterhouse Cooper's Strategy&; London United Kingdom

3. Italian Medicines Agency; Rome Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference70 articles.

1. European Medicines Agency. Adaptive Pathways http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp 2014

2. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients;Eichler;Clin. Pharmacol. Ther.,2015

3. Adaptive licensing” or “adaptive pathways”: deregulation under the guise of earlier access;International Society of Drug Bulletins;The International Society of Drug Bulletins (ISDB)

4. Managed entry agreements for pharmaceuticals: the European experience;Ferrario;The London School of Economics and Political Science,2013

5. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers;Adamski;BMC Health Serv. Res.,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes;Management Science;2022-12-15

2. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems;Frontiers in Medical Technology;2022-06-16

3. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review;Value in Health;2022-04

4. Drug Prices and Value of Oncology Drugs in Italy;Value in Health;2021-09

5. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy;Frontiers in Pharmacology;2021-08-10